Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 11/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6603633 | 0.84 | NPBWR1 (0.52) | NPBWR1MCHR1UCHL1HTTL3MBTL1 | |
| SCHEMBL2456576 | 0.82 | NPBWR1 (0.53) | NPBWR1MCHR1UCHL1CYP19A1 | |
| SCHEMBL29483303 | 0.81 | NPBWR1 (0.52) | NPBWR1MCHR1UCHL1CYP19A1L3MBTL1 | |
| SCHEMBL3573767 | 0.79 | L3MBTL1 (0.48) | ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL8886643 | 0.78 | NPBWR1 (0.51) | NPBWR1MCHR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2050022 | 0.78 | UCHL1 (0.57) | NPBWR1MCHR1UCHL1ALDH1A1HTT | |
| SCHEMBL15130259 | 0.77 | NPBWR1 (0.45) | NPBWR1MCHR1UCHL1ALDH1A1HTT | |
| SCHEMBL366891 | 0.77 | UCHL1 (0.46) | NPBWR1MCHR1UCHL1ALDH1A1HTT | |
| SCHEMBL4680080 | 0.76 | NPBWR1 (0.47) | NPBWR1MCHR1UCHL1CYP19A1 | |
| SCHEMBL23799145 | 0.76 | NPBWR1 (0.39) | NPBWR1MCHR1HSP90AA1UCHL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117986258-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-8513252-B2 | Pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2013-08-20 | — | — | US | disclosed |
| EP-2456769-B1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-06-26 | — | — | EP | disclosed |
| EP-2456769-A1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2012-05-30 | — | — | EP | disclosed |
| US-20120122907-A1 | Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NISSAN MOTOR CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| WO-2011010222-A1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122907-A1 | Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM1, GRM4, GRM3 | NPBWR1 476/4885MCHR1 416/4885HSP90AA1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.